代償期HBV肝硬化患者接受恩替卡韋治療後與健康相關的生活

StephenW

代償期HBV肝硬化患者接受恩替卡韋治療後與健康相關的生活質量得到改善

    吳曉寧、洪家、周嘉玲、孫亞夢、李磊、謝文、樸紅新、徐曉元、江偉、波峰、陳永鵬、徐明儀、吉林程、孟彤彤、王炳瓊、陳書艷、孔媛媛, 歐小娟, Hong You & Jidong Jia

Hepatology International 第 15 卷，第 1318–1327 頁（2021）引用本文

    50 次訪問

    指標詳情

抽象的
背景與目標

抗病毒治療可有效減少 HBV 肝硬化的疾病進展。然而，抗病毒治療對代償期 HBV 肝硬化患者健康相關生活質量 (HRQoL) 的長期影響尚不清楚。
方法

本研究招募了參加基於恩替卡韋治療的隨機對照試驗的代償性 HBV 肝硬化患者，如果他們在 5 年隨訪時有 HRQoL 評分或在隨訪期間發生肝臟相關事件 (LRE)被包括在內。 HRQoL 在基線和每年隨訪期間使用 36 項簡表健康調查 (SF-36) 和 EuroQol-5D (EQ-5D) 進行測量。 LRE 被定義為失代償、HCC 或死亡的發展。
結果

本研究共納入 161 名患者，中位年齡為 48.0 (41.0, 53.0) 歲，77.6% 為男性，37.2% 為 HBeAg 陽性。在 5 年內，45 名患者發生了 LRE。 SF-36 的所有八個維度在抗病毒治療 5 年後都有顯著改善（所有 p < 0.001），除了身體功能外，所有維度的改善都超過五分。在 EQ-5D 中所有五個維度都沒有問題的患者比例從 57.8% 增加到 72.0%；視覺模擬量表 (VAS) 和效用指數 (UI) 顯著增加（VAS 79.8 ± 16.4 至 84.4 ± 13.2，UI 0.91 ± 0.13 至 0.95 ± 0.10，兩者均 p <0 ）。大多數 LRE 患者在隨訪期間 HRQoL 有所改善或保持穩定，甚至根據 Baveno VI 臨床顯著性門靜脈高壓標准進行分層。
結論

經過 5 年的 ETV 治療，代償期 HBV 肝硬化患者的 HRQoL 顯著改善。 (NCT01943617, NCT02849132)

StephenW

Health-related quality of life improves after entecavir treatment in patients with compensated HBV cirrhosis

    Xiaoning Wu, Jia Hong, Jialing Zhou, Yameng Sun, Lei Li, Wen Xie, Hongxin Piao, Xiaoyuan Xu, Wei Jiang, Bo Feng, Yongpeng Chen, Mingyi Xu, Jilin Cheng, Tongtong Meng, Bingqiong Wang, Shuyan Chen, Yuanyuan Kong, Xiaojuan Ou, Hong You & Jidong Jia

Hepatology International volume 15, pages 1318–1327 (2021)Cite this article

    50 Accesses

    Metrics details

Abstract
Background and aim

Antiviral therapy is effective in decreasing disease progression in HBV cirrhosis. However, the long-term effect of antiviral therapy on health-related quality of life (HRQoL) in patients with compensated HBV cirrhosis is unknown.
Methods

The patients with compensated HBV cirrhosis enrolled in a randomized controlled trial of entecavir-based therapy were recruited in the present study, if they had HRQoL score at 5-year follow-up or who developed liver-related events (LRE) during follow-up were included. HRQoL was measured with 36-Item Short-Form Health Survey (SF-36) and EuroQol-5D (EQ-5D) at baseline and yearly during follow-up. LRE was defined as the development of decompensation, HCC, or death.
Results

A total of 161 patients were included in the present study, with a median age of 48.0 (41.0, 53.0) years, 77.6% being male and 37.2% being HBeAg-positive. During 5 years, 45 patients developed LRE. All eight dimensions of SF-36 were significantly improved after 5 years of antiviral therapy (all p < 0.001), with all dimensions improved more than five points except for physical functioning. Proportion of patients reporting no problems in all five dimensions in EQ-5D increased from 57.8 to 72.0%; visual analogue scale (VAS) and utility index (UI) increased significantly (VAS 79.8 ± 16.4 to 84.4 ± 13.2, UI 0.91 ± 0.13 to 0.95 ± 0.10, both p < 0.001). HRQoL improved or kept stable in the majority of patients who had LRE during follow-up, even stratified by Baveno VI criteria for clinically significant portal hypertension.
Conclusion

After 5 years of ETV treatment, HRQoL significantly improved in patients with compensated HBV cirrhosis. (NCT01943617, NCT02849132)

StephenW

https://link.springer.com/conten ... 072-021-10240-4.pdf

小牡丹

根据我的化验结果，同意这样的结论。

小牡丹

抗病毒离治愈差十万八千里。期待治愈药2022年井喷式出现。